Active Biotech

Active Biotech (STO:ACTI) Lund, Sweden, December 10, 2008 - Active Biotech AB (NASDAQ OMX Nordic: ACTI) has presented results related to the cancer project ANYARA where the effect of ANYARA was studied in combination with other established tumor therapies in experimental models of cancer.

Active Biotech (STO:ACTI) In accordance with the decision by the Annual General Meeting on May 7, 2008, the election committee shall consist of representatives from the three largest shareholders as at the end of October and the Chairman of the Board.

Active Biotech (STO:ACTI) - Recruitment Still Ongoing For Second, Pivotal Phase III Study, Bravo - Jerusalem, Israel and Lund, Sweden, November 18, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the Phase III clinical trial, Allegro, in relapsing-remitting multiple sclerosis (RRMS). The pivotal Allegro study is designed to evaluate the efficacy, safety and tolerability of the oral investigational compound, laquinimod, versus placebo in the treatment of RRMS.

Active Biotech (STO:ACTI) - Laquinimod -- positive data presented from extension study

Active Biotech (STO:ACTI) Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

Active Biotech (STO:ACTI) Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.

Active Biotech (STO:ACTI) Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.

Active Biotech (STO:ACTI) Lund, Sweden, October 17, 2008 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) today announce information regarding the candidate drug RhuDex® for the treatment of rheumatoid arthritis.

Active Biotech (STO:ACTI) - New Crossover Data Presented at the World Congress on Treatment and Research in Multiple Sclerosis Shows Significant Reduction of Gadolinium-Enhancing Lesions -

Active Biotech (STO:ACTI) Lund, Sweden, 17 September 2008 - Active Biotech (OMX Nordic: ACTI) is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 23 at the Grand Hyatt Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.